ReviewJournal of hematology & oncology2010
Ovarian cancer immunotherapy: opportunities, progresses and challenges.
Review in Journal of hematology & oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer.Cancer immunology, immunotherapy : CII · 2026Article
- The Role of the Plasminogen Activator Inhibitor 1 (Global medical genetics · 2024Review
- CD4Journal of translational medicine · 2023Article
- Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.Experientia supplementum (2012) · 2022Article
- Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.Advanced therapeutics · 2020Article
- microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.Journal of ovarian research · 2020Article
- MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.Inflammation · 2019Article
- Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues.Oncotarget · 2018Article
- Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Journal of translational medicine · 2018Article
- The immunopeptidomic landscape of ovarian carcinomas.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.Scientific reports · 2017Article
- Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.Cancer biology & therapy · 2017Article
- Article
- Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.Cancer management and research · 2017Review
- IL‑6 and IL‑8 enhance factor H binding to the cell membranes.Molecular medicine reports · 2016Article
- Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Acta biochimica et biophysica Sinica · 2016Review
- Production and Characterization of a Novel Monoclonal Antibody Against Human Sortilin.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2015Article
- The effect of sortilin silencing on ovarian carcinoma cells.Avicenna journal of medical biotechnology · 2014Article
- Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.British journal of cancer · 2014Article
- Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.